Dr. Jennifer Doudna, Nobel laureate and Scribe co-founder, shares her vision for the future of gene editing with Bloomberg Originals host Emily Chang.

Full video and article links in thread 🧵

This Juneteenth, we invited our Alameda neighbor, Sips Global Tea, to share their knowledge and collection of global teas sourced from Africa, Asia, South America, and Europe with our team.

Thanks for leading us through the craft and culture of tea blending for a day of learning and community 🍵

We’re excited to share that @cirmnews.bsky.social has awarded Scribe more than $25 million through its Preclinical Development Program to accelerate the advancement of two preclinical programs targeting cardiovascular and metabolic disease.

Press release in thread 📣

Our go-to recipe for a team brunch? Good food and even better company. At Scribe, we have it down to a science. 🧑‍🍳

At #EASCongress2026, we presented late-breaking preclinical data on our lead cardiometabolic program STX-1150. These data support STX-1150 as a clinical-stage epigenetic silencing therapy designed to achieve years of LDL-C lowering after a single dose.

Study highlights below ⬇️

Announcing our first clinical trial.

Scribe has secured regulatory clearance from Australia’s Therapeutic Goods Administration to initiate a first-in-human clinical study of STX-1150 for the treatment of hypercholesterolemia, a major driver of atherosclerotic cardiovascular disease.

Details🧵

At #ASGCT2026, we presented preclinical data highlighting the latest advances across our engineered #CRISPR technologies for epigenetic silencing and gene editing.

Highlights of our three oral presentations below and in thread 🧵

www.businesswire.com/news/home/20...

Two #ASGCT26 oral presentations tomorrow!

🔹Engineering CasX for therapeutic-grade in vivo editing with DeepXE, a predictive model for guide potency
🔹ADDing a lock to epigenome editing: DNMT3A allostery enhances specificity and potency of CRISPR-CasX-based epigenetic repressors

Next month, join us at the 2026 @asgct.bsky.social Annual Meeting and @eassociety.bsky.social!

Happy #DNADay26! Today, we celebrate the ongoing innovations in genetics and epigenetics that are shaping the future of human health. 🧬

At Scribe, we're committed to bringing novel #CRISPR-based genetic medicines to patients in need.

Learn more at scribetx.com.

This #WorldHealthDay, we’re recognizing the importance of scientific progress in improving lives.

At Scribe, that mission continues to guide our work every day to advance novel #CRISPR-based genetic medicines for patients, starting with those with cardiovascular disease.

To celebrate the start of spring, our team traded lab coats 🥼 for garden gloves for an afternoon of planting, propagating, and building out a community herb garden. 🌱

A fun way to welcome the season and spend time together outside the lab!